Latest research on Paclitaxel

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia]

Latest findings

These 2-ME analogues were probed in combination with other drugs, for example: Docetaxel in breast cancer (28) or Paclitaxel in head and neck squamous cell carcinoma with good results (45). [source, 2016]
Each tumor cell line was exposed to each test compound at concentrations of 0.001, 0.01, 0.1, 1, and 10 μM in triplicate for 48 h, and Paclitaxel and cis-platinum were used as positive controls. [source, 2016]
Moreover, linalool had an Analgesic effect in an animal model of acute pain induced by Paclitaxel, a widely used chemotherapy agent [13]. [source, 2016]
Many other CPPs are reported delivering therapeutic peptides (Antimicrobial and anticancer peptides), peptide nucleic acid (PNA), and small molecule drugs (e.g. Doxorubicine, Paclitaxel, etc.) as shown in Figure 2. [source, 2016]
In both the FAS and PAS (respectively), Paclitaxel (26% and 25%), Docetaxel (17% and 18%), trastuzumab (14% and 11%), Vinorelbine (12% and 11%), and Capecitabine (9% and 11%) were the most commonly used agents in “non-standard” regimens. [source, 2016]
Among patients with ovarian cancer, the most common “standard” regimens in the FAS and PAS (n=157 and n=79, respectively) were Carboplatin plus Paclitaxel (29% in both populations) and Carboplatin plus Gemcitabine (9% and 11%, respectively). [source, 2016]
Carboplatin (17% and 20%), Paclitaxel (16% and 14%), Topotecan (12% and 9%), Gemcitabine (10% and 15%), and bevacizumab (10% and 11%) were the most commonly used agents in “non-standard” regimens (for FAS and PAS, respectively). [source, 2016]
CSCs/CS-LCs have been isolated from the NCI-H460 lung cancer cell line [10, 15, 16] and are associated with chemoresistance to anticancer drugs such as Cisplatin, Etoposide, Doxorubicin, and Paclitaxel [13, 15, 17, 18]. [source, 2016]
Sox2, via the PI3K/AKT pathway, has been recently shown to be involved in resistance to conventional anticancer drugs such as Paclitaxel in prostate [36] and ovarian [37] cancers. [source, 2016]
For refractory thymoma and thymic carcinoma, the NCCN guidelines [12] recommend single-agent or non-platinum-based chemotherapy, such as Etoposide [25], Gemcitabine [26], Paclitaxel [27], Ifosfamide [28], Pemetrexed [29], 5-Fluorouracil (5-FU) and Leucovorin [30], and Octreotide (including long acting-formulation) plus Prednisolone [31]. [source, 2016]